All Stories

  1. Unveiling the “Three-Finger Pharmacophore” Required for p53-MDM2 Inhibition by Saturation-Transfer Difference (STD) NMR Initial Growth-Rates Approach

    Article • Chemistry - A European Journal, March 2016, Wiley

    Professor Mark Searcey

  2. A natural product inspired fragment-based approach towards the development of novel anti-bacterial agents

    Article • MedChemComm, January 2016, Royal Society of Chemistry

    Professor Mark Searcey

  3. Identification of a new p53/MDM2 inhibitor motif inspired by studies of chlorofusin

    Article • Bioorganic & Medicinal Chemistry Letters, November 2015, Elsevier

    Professor Mark Searcey

  4. Solid-Phase Synthesis of Duocarmycin Analogues and the Effect of C-Terminal Substitution on Biological Activity

    Article • The Journal of Organic Chemistry, October 2015, American Chemical Society (ACS)

    Professor Mark Searcey

  5. The Handbook of Medicinal Chemistry-Principles and Practice. Edited by Andrew Davis and Simon E. Ward

    Article • ChemMedChem, September 2015, Wiley

    Professor Mark Searcey

  6. Probing cytochrome P450-mediated activation with a truncated azinomycin analogue

    Article • MedChemComm, January 2015, Royal Society of Chemistry

    Professor Mark Searcey

  7. Identification and characterisation of a G-quadruplex forming sequence in the promoter region of nuclear factor (erythroid-derived 2)-like 2 (Nrf2)

    Article • Biochemical and Biophysical Research Communications, April 2014, Elsevier

    Professor Mark Searcey

  8. Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity

    Article • Journal of Medicinal Chemistry, August 2013, American Chemical Society (ACS)

    Professor Mark Searcey

  9. Abstract 2224: Re-engineering of the duocarmycin structural architecture enables tumour-selective CYP2W1-mediated drug activation in human colon cancer xenografts.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Professor Mark Searcey

  10. A rapid screen for molecules that form duplex to duplex crosslinks in DNA

    Article • Chemical Communications, January 2013, Royal Society of Chemistry

    Professor Mark Searcey

  11. Non-covalent duplex to duplex crosslinking of DNA in solution revealed by single molecule force spectroscopy

    Article • Organic & Biomolecular Chemistry, January 2013, Royal Society of Chemistry

    Professor Mark Searcey

  12. Anti-inflammatory Effect of a Cell-Penetrating Peptide Targeting the Nrf2/Keap1 Interaction

    Article • ACS Medicinal Chemistry Letters, May 2012, American Chemical Society (ACS)

    Professor Mark Searcey

  13. Synthesis of Small Molecules Targeting Multiple DNA Structures using Click Chemistry

    Article • ChemMedChem, February 2012, Wiley

    Professor Mark Searcey

  14. Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity

    Article • Chemical Communications, January 2011, Royal Society of Chemistry

    Professor Mark Searcey

  15. A small molecule that induces assembly of a four way DNA junction at low temperature

    Article • Chemical Communications, January 2011, Royal Society of Chemistry

    Professor Mark Searcey

  16. Design and synthesis of threading intercalators to target DNA

    Article • Bioorganic & Medicinal Chemistry Letters, December 2010, Elsevier

    Professor Mark Searcey

  17. Faculty of 1000 evaluation for A small-molecule inducer of the antioxidant response element.

    Article • August 2010, Faculty of 1000, Ltd.

    Professor Mark Searcey

  18. ChemInform Abstract: Synthesis and Evaluation of Duocarmycin and CC-1065 Analogues Containing Modifications in the Subunit Linking Amide.

    Article • ChemInform, June 2010, Wiley

    Professor Mark Searcey

  19. ChemInform Abstract: Total Synthesis and Comparative Evaluation of Luzopeptin A-C and Quinoxapeptin A-C.

    Article • ChemInform, June 2010, Wiley

    Professor Mark Searcey

  20. ChemInform Abstract: Bifunctional Alkylating Agents Derived from Duocarmycin SA: Potent Antitumor Activity with Altered Sequence Selectivity.

    Article • ChemInform, June 2010, Wiley

    Professor Mark Searcey

  21. ChemInform Abstract: A Convenient Access to Benzo-Substituted Phthalazines as Potential Precursors to DNA Intercalators.

    Article • ChemInform, May 2010, Wiley

    Professor Mark Searcey

  22. ChemInform Abstract: Synthesis and Evaluation of 9-Aminoacridines Derived from Benzyne Click Chemistry.

    Article • ChemInform, February 2010, Wiley

    Professor Mark Searcey

  23. ChemInform Abstract: Targeting Higher-Order DNA: Beyond the G-Quadruplex

    Article • ChemInform, December 2009, Wiley

    Professor Mark Searcey

  24. Chemical and Biological Explorations of the Family of CC-1065 and the Duocarmycin Natural Products

    Article • Current Topics in Medicinal Chemistry, November 2009, Bentham Science Publishers

    Professor Mark Searcey

  25. Synthesis and evaluation of 9-aminoacridines derived from benzyne click chemistry

    Article • Bioorganic & Medicinal Chemistry Letters, October 2009, Elsevier

    Professor Mark Searcey

  26. Targeting Higher-Order DNA: Beyond the G-Quadruplex

    Article • ChemBioChem, September 2009, Wiley

    Professor Mark Searcey

  27. Rationally Engineered Total Biosynthesis of a Synthetic Analogue of a Natural Quinomycin Depsipeptide inEscherichia coli

    Article • ChemBioChem, August 2009, Wiley

    Professor Mark Searcey

  28. ChemInform Abstract: The Isolation, Total Synthesis and Structure Elucidation of Chlorofusin, a Natural Product Inhibitor of the p53-MDM2 Protein-Protein Interaction

    Article • ChemInform, July 2009, Wiley

    Professor Mark Searcey

  29. Evaluation of chlorofusin, its seven chromophore diastereomers, and key analogues

    Article • Tetrahedron Letters, July 2009, Elsevier

    Professor Mark Searcey

  30. Design, Synthesis, and Evaluation of an α-Helix Mimetic Library Targeting Protein−Protein Interactions

    Article • Journal of the American Chemical Society, April 2009, American Chemical Society (ACS)

    Professor Mark Searcey

  31. The isolation, total synthesis and structure elucidation of chlorofusin, a natural product inhibitor of the p53–MDM2 protein–protein interaction

    Article • Natural Product Reports, January 2009, Royal Society of Chemistry

    Professor Mark Searcey

  32. Optimizing drugs for local delivery

    Article • Drug News & Perspectives, January 2009, Prous Science

    Professor Mark Searcey

  33. DNA Binding by Analogues of the Bifunctional Intercalator TANDEM

    Article • Biochemistry, July 2008, American Chemical Society (ACS)

    Professor Mark Searcey

  34. Chemistry in Cancer Research: A Vital Partnership

    Article • Cancer Research, July 2007, American Association for Cancer Research (AACR)

    Professor Mark Searcey

  35. Solid-Phase Synthesis of Chlorofusin Analogues

    Article • The Journal of Organic Chemistry, July 2007, American Chemical Society (ACS)

    Professor Mark Searcey

  36. Bisintercalator Natural Products with Potential Therapeutic Applications: Isolation, Structure Determination, Synthetic and Biological Studies

    Article • ChemInform, May 2007, Wiley

    Professor Mark Searcey

  37. Ligand Bridging of the DNA Holliday Junction: Molecular Recognition of a Stacked-X Four-Way Junction by a Small Molecule

    Article • Angewandte Chemie, May 2007, Wiley

    Professor Christine J Cardin, Professor Mark Searcey

  38. Ligand Bridging of the DNA Holliday Junction: Molecular Recognition of a Stacked-X Four-Way Junction by a Small Molecule

    Article • Angewandte Chemie International Edition, May 2007, Wiley

    Professor Christine J Cardin, Professor Mark Searcey

  39. Chemistry in Cancer Research: A Vital Partnership

    Article • ACS Chemical Biology, May 2007, American Chemical Society (ACS)

    Professor Mark Searcey

  40. Stereoselectivity, Sequence Specificity and Mechanism of Action of the Azinomycin Epoxide.

    Article • ChemInform, January 2007, Wiley

    Professor Mark Searcey

  41. Bisintercalator natural products with potential therapeutic applications: isolation, structure determination, synthetic and biological studies

    Article • Natural Product Reports, January 2007, Royal Society of Chemistry

    Professor Mark Searcey

  42. Synthesis of DNA-Directed Pyrrolidinyl and Piperidinyl Confined Alkylating Chloroalkylaminoanthraquinones:  Potential for Development of Tumor-Selective N -Oxides

    Article • Journal of Medicinal Chemistry, November 2006, American Chemical Society (ACS)

    Professor Mark Searcey

  43. Stereoselectivity, Sequence Specificity and Mechanism of Action of the Azinomycin Epoxide

    Article • ChemBioChem, September 2006, Wiley

    Professor Mark Searcey

  44. Synthesis of distamycin A polyamides targeting G-quadruplex DNA

    Article • Organic & Biomolecular Chemistry, January 2006, Royal Society of Chemistry

    Professor Mark Searcey

  45. Antitumour Antibiotics with Potent Activity Against Multidrug Resistant (MDR) Staphylococcus aureus: A New Approach to Targeting Resistant Bacteria

    Article • Medicinal Chemistry, November 2005, Bentham Science Publishers

    Professor Mark Searcey

  46. Development of Nonsymmetrical 1,4-Disubstituted Anthraquinones That Are Potently Active against Cisplatin-Resistant Ovarian Cancer Cells

    Article • Journal of Medicinal Chemistry, October 2005, American Chemical Society (ACS)

    Professor Mark Searcey

  47. Efficient Solid-Phase-Based Total Synthesis of the Bisintercalator TANDEM

    Article • The Journal of Organic Chemistry, September 2005, American Chemical Society (ACS)

    Professor Mark Searcey

  48. Truncated Azinomycin Analogues Intercalate into DNA.

    Article • ChemInform, June 2005, Wiley

    Professor Mark Searcey

  49. Truncated azinomycin analogues intercalate into DNA

    Article • Bioorganic & Medicinal Chemistry Letters, February 2005, Elsevier

    Professor Mark Searcey

  50. Design and synthesis of a DNA-crosslinking azinomycin analogue

    Article • Organic & Biomolecular Chemistry, January 2005, Royal Society of Chemistry

    Professor Mark Searcey

  51. Resistance in Cancer: A Target for Drug Discovery

    Article • Current Medicinal Chemistry - Anti-Cancer Agents, September 2004, Bentham Science Publishers

    Professor Mark Searcey

  52. A Mild Procedure for the Production of Secondary Amines from Oximes and Benzisoxazoles.

    Article • ChemInform, December 2003, Wiley

    Professor Mark Searcey

  53. Solid-Phase Synthesis of the Cyclic Peptide Portion of Chlorofusin, an Inhibitor of p53-MDM2 Interactions

    Article • Organic Letters, December 2003, American Chemical Society (ACS)

    Professor Mark Searcey

  54. A mild procedure for the production of secondary amines from oximes and benzisoxazoles

    Article • Tetrahedron Letters, August 2003, Elsevier

    Professor Mark Searcey

  55. Duocarmycins - Natures Prodrugs?

    Article • Current Pharmaceutical Design, July 2002, Bentham Science Publishers

    Professor Mark Searcey

  56. A convenient access to benzo-substituted phthalazines as potential precursors to DNA intercalators

    Article • Tetrahedron Letters, September 2001, Elsevier

    Professor Mark Searcey

  57. Synthesis and evaluation of a novel bleomycin A2 analogue: continuing assessment of the linker domain

    Article • Tetrahedron Letters, December 2000, Elsevier

    Professor Mark Searcey

  58. Synthesis and Evaluation of 1,2,8,8a-Tetrahydrocyclopropa[ c ]pyrrolo[3,2- e ]indol-4(5 H )-one, the Parent Alkylation Subunit of CC-1065 and the Duocarmycins:  Impact of the Alkylation Subunit Substituents and Its Implications for DNA Alkylation Cata...

    Article • The Journal of Organic Chemistry, June 2000, American Chemical Society (ACS)

    Professor Mark Searcey

  59. Bifunctional alkylating agents derived from duocarmycin SA: potent antitumor activity with altered sequence selectivity

    Article • Bioorganic & Medicinal Chemistry Letters, March 2000, Elsevier

    Professor Mark Searcey

  60. Total Synthesis and Comparative Evaluation of Luzopeptin A−C and Quinoxapeptin A−C

    Article • Journal of the American Chemical Society, December 1999, American Chemical Society (ACS)

    Professor Mark Searcey

  61. Synthesis and Evaluation of Duocarmycin and CC-1065 Analogues Containing Modifications in the Subunit Linking Amide

    Article • The Journal of Organic Chemistry, July 1999, American Chemical Society (ACS)

    Professor Mark Searcey

  62. Critical Role of the Linking Amide in CC-1065 and the Duocarmycins:  Implications on the Source of DNA Alkylation Catalysis

    Article • Journal of the American Chemical Society, November 1998, American Chemical Society (ACS)

    Professor Mark Searcey

  63. Synthesis of CC-1065 and duocarmycin analogs via intramolecular aryl radical cyclization of a tethered vinyl chloride

    Article • Tetrahedron Letters, April 1998, Elsevier

    Professor Mark Searcey

  64. Bleomycin mimics. Design and synthesis of an acridine derivative which cleaves DNA in a sequence-neutral manner

    Article • Journal of the Chemical Society Perkin Transactions 2, January 1997, Royal Society of Chemistry

    Professor Mark Searcey

  65. DNA threading agents: effect of sidechain bulk on DNA binding and cytotoxicity of 9-anilinoacridine-4-carboxamides

    Article • Bioorganic & Medicinal Chemistry Letters, August 1996, Elsevier

    Professor Mark Searcey

  66. Catalytic antibody activity elicited by active immunisation. Evidence for natural variation involving preferential stabilization of the transition state

    Article • European Journal of Biochemistry, May 1993, Wiley

    Professor Mark Searcey

  67. Polyclonal antibody-catalysed amide hydrolysis

    Article • Biochemical Journal, June 1992, Portland Press Ltd.

    Professor Mark Searcey

  68. A polyclonal antibody preparation with Michaelian catalytic properties

    Article • Biochemical Journal, November 1991, Portland Press Ltd.

    Professor Mark Searcey

  69. Polyclonal-antibody-catalysed hydrolysis of an aryl nitrophenyl carbonate

    Article • Biochemical Society Transactions, August 1990, Portland Press Ltd.

    Professor Mark Searcey

  70. Improved Syntheses of N-Substituted Nitroimidazoles

    Article • Synthetic Communications, April 1989, Taylor & Francis

    Professor Mark Searcey

  71. The Azinomycins. Discovery, Synthesis, and DNA-Binding Studies

    Article • Wiley

    Professor Mark Searcey

  72. Faculty of 1000 evaluation for Total synthesis, stereochemical reassignment, and absolute configuration of chlorofusin.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  73. Faculty of 1000 evaluation for Structural basis of DNA quadruplex recognition by an acridine drug.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  74. Faculty of 1000 evaluation for Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  75. Faculty of 1000 evaluation for Transcription of Click-Linked DNA in Human Cells.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  76. Faculty of 1000 evaluation for Inhibition of Ras Signaling by Blocking Ras-Effector Interactions with Cyclic Peptides.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  77. Faculty of 1000 evaluation for A Model Of Smart G-Quadruplex Ligand

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  78. Faculty of 1000 evaluation for Optimized Fmoc solid-phase synthesis of the cysteine-rich peptide linaclotide.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  79. Faculty of 1000 evaluation for Benzyne click chemistry: synthesis of benzotriazoles from benzynes and azides.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  80. Faculty of 1000 evaluation for Site-selective bromination of vancomycin.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  81. Faculty of 1000 evaluation for Turning a scorpion toxin into an antitumor miniprotein.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  82. Faculty of 1000 evaluation for Biomimetic synthesis and structural reassignment of the tridachiahydropyrones.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  83. Faculty of 1000 evaluation for Ruthenium-catalyzed oxidation of alcohols into amides.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  84. Faculty of 1000 evaluation for Exploring isonitrile-based click chemistry for ligation with biomolecules.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  85. Faculty of 1000 evaluation for Small-molecule-mediated G-quadruplex isolation from human cells.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  86. Faculty of 1000 evaluation for A regenerative approach to the treatment of multiple sclerosis.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  87. Faculty of 1000 evaluation for Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  88. Faculty of 1000 evaluation for Ion-dependent conformational switching by a DNA aptamer that induces remyelination in a mouse model of multiple sclerosis.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  89. Faculty of 1000 evaluation for Neopetrosiamides, peptides from the marine sponge Neopetrosia sp. that inhibit amoeboid invasion by human tumor cells.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  90. Faculty of 1000 evaluation for Depurinating acylfulvene-DNA adducts: characterizing cellular chemical reactions of a selective antitumor agent.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  91. Faculty of 1000 evaluation for Organocatalytic synthesis of (2S,3R)-3-hydroxy-3-methyl-proline (OHMePro), a component of polyoxypeptins, and relatives using OHMePro itself as a catalyst.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  92. Faculty of 1000 evaluation for Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  93. Faculty of 1000 evaluation for New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  94. Faculty of 1000 evaluation for Synthesis and biological evaluation of 10,11-dihydrodictyostatin, a potent analogue of the marine anticancer agent dictyostatin.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  95. Faculty of 1000 evaluation for Synthesis of a 35-member stereoisomer library of bistramide A: evaluation of effects on actin state, cell cycle and tumor cell growth.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  96. Faculty of 1000 evaluation for Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  97. Faculty of 1000 evaluation for From Complex Natural Products to Simple Synthetic Mimetics by Computational De Novo Design.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  98. Faculty of 1000 evaluation for The Dynamic Character of the BCL2 Promoter i-Motif Provides a Mechanism for Modulation of Gene Expression by Compounds That Bind Selectively to the Alternative DNA Hairpin Structure.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey

  99. Faculty of 1000 evaluation for Anticancer Activity and Cellular Repression of c-MYC by the G-Quadruplex-Stabilizing 11-Piperazinylquindoline Is Not Dependent on Direct Targeting of the G-Quadruplex in the c-MYC Promoter.

    Article • Faculty of 1000, Ltd.

    Professor Mark Searcey